MARS preconditioning for living donor liver transplantation: Panacea or placebo?

Liver International

Volumn 25, Issue 4, 2005, Pages 692-695

  Brown Jr , R S ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMMONIA; BILIRUBIN; TOXIN;

AMMONIA BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; DATA ANALYSIS; DEVICE; DIALYSIS; EDITORIAL; HEPATIC ENCEPHALOPATHY; HUMAN; KIDNEY FUNCTION; LIVER DYSFUNCTION; LIVER FAILURE; LIVER TRANSPLANTATION; LIVING DONOR; MEAN ARTERIAL PRESSURE; OUTCOMES RESEARCH; SURVIVAL RATE; SYSTEMIC VASCULAR RESISTANCE;

HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; LIVER, ARTIFICIAL; LIVING DONORS; PLACEBO EFFECT; RENAL DIALYSIS; SORPTION DETOXIFICATION; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 22844432333     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01133.x     Document Type: Editorial

References (10)

1. Akyildiz M, Karasu Z, Arikan C, Kilic M, Zeytunlu M, Gunsar F, Ersoz G, et al. Impact of pretransplant MELD score on posttransplant outcome in living donor liver transplantation. Transplant Proc 2004; 36: 1442-4.
2. Abt P L, Mange K C, Olthoff K M, Markmann J F, Reddy K R, Shaked A. Allograft survival following adult-to-adult living donor liver transplantation. Am J Transplant 2004; 4: 1302-7.
3. Demetriou A A, Brown Jr. R S, Busuttil R W, Fair J, McGuire B M, Rosenthal P, Am Esch II J S, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004; 239: 660-7 (discussion 667-670).
4. Mitzner S R, Stange J, Klammt S, Risler T, Erley C M, Bader B D, Berger E D, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transplant 2000; 6: 277-86.
5. Stange J, Mitzner S R, Klammt S, Freytag J, Peszynski P, Loock J, Hickstein H, et al. Liver support by extracorporeal blood purification: a clinical observation. Liver Transplant 2000; 6: 603-13.
6. Novelli G, Rossi M, Pretagostini R, Poli L, Peritore D, Berloco P, Di Nicuolo A, et al. Use of MARS in the treatment of acute liver failure: preliminary monocentric experience. Transplant Proc 2001; 33: 1942-4.
7. Stange J, Hassanein T I, Mehta R, Mitzner S R, Bartlett R H. The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif Organs 2002; 26: 415-30.
8. Hassanein T, Tofteng F, Brown Jr. R. S., McGuire B, Metha R, Larsen F S, Gornbein J, et al. Efficacy of albumin dialysis (MARS) in patients with cirrhosis and advanced grades of hepatic encephalopathy: a prospective, controlled, randomized, multicenter trial. Hepatology 2004; 40: pLB04.
9. Choi Y S, Bae S, Yoon S K, Cho S, Yang J M, Han J Y, Ahn B M, et al. Preconditioning by extracorporeal liver support (MARS) of patients with cirrhosis and severe liver failure evaluated for living donor liver transplantation - a pilot study. Liver Int 2005; 25: 740-5.
10. Merion R M, Schaubel D E, Dykstra D M, Freeman R B, Port F K, Wolfe R A. The survival benefit of liver transplantation. Am J Transplant 2005; 5: 307-13.